bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figure 1 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Supplementary figure 1. Effect of free DM1 in vitro on reduction of viability of CRC cells
Supplementary Table 3 from Efficacy of Anti-RON Antibody Zt/g4–Drug Maytansinoid Conjugation (Anti-RON ADC) as a Novel Therapeutics for Targeted Colorectal Cancer Therapy
Authors: Feng Liang , Yao Hang-Ping , Wang Wei , Zhou Yong-Qing , Zhou Jianwei , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

Supplementary Table 3. Effect of Anti-RON ADCs on cell cycles of Three Colorectal Cancer Cell Lines
Supplementary Figure Legend, Tables 1 - 3 from Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
Authors: Peeters Marc , Oliner Kelly S. , Parker Alex , Siena Salvatore , Van Cutsem Eric , Huang Jing , Humblet Yves , Van Laethem Jean-Luc , André Thierry , Wiezorek Jeffrey , Reese David , Patterson Scott D.
Published: April 2023

PDF file - 109K, PCR Primer Sequences; Baseline Demographic and Clinical Characteristics for Patients With and Without Available Multigene Information; Mutations Identified In Available Patient Tumor Specimens
Supplementary Figures 1 - 20 from Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Authors: Jahangiri Arman , De Lay Michael , Miller Liane M. , Carbonell W. Shawn , Hu Yu-Long , Lu Kan , Tom Maxwell W. , Paquette Jesse , Tokuyasu Taku A. , Tsao Sean , Marshall Roxanne , Perry Arie , Bjorgan Kirsten M. , Chaumeil Myriam M. , Ronen Sabrina M. , Bergers Gabriele , Aghi Manish K.
Published: April 2023

PDF file - 3201K, Supplementary Figure S1. Real time RT PCR analysis of BRGs compared to paired pre-treatment GBMs; Supplementary Figure S2. FISH reveals no change in c-Met amplification after bevacizumab resistance as compared to before; Supplementary Figure S3. Changes in Pearson correlation coefficients to 3 previously described molecular GBM subtypes in BRGs and bevacizumab-na�ve GBMs after recurrence; Supplementary Figure S4. C-Met phosphorylation increases after bevacizumab resistance; Supplementary Figure S5. Increased expression of phosphorylated FAK, a downstream effector of c-Met, in bevacizumab-resistant glioblastomas (BRGs) compared to before treatment; Supplementary Figure S6. Increased expression of phosphorylated STAT3, a downstream effector of c-Met, in bevacizumab-resistant glioblastomas (BRGs) compared to before treatment; Supplementary Figure S7. Hypoxia after bevacizumab resistance versus bevacizumab-na�ve recurrence; Supplementary Figure S8. Endothelial cells do not contribute to increased c-Met expression after bevacizumab resistance; Supplementary Figure S9. Hypoxia increases HGF expression in U87-IgG and U87-BevR cells; Supplementary Figure S10. Xenografts established from BRGs analyzed by immunohistochemistry; Supplementary Figure S11. Immunofluorescent staining of xenografts established from bevacizumab-na�ve GBMs; Supplementary Figure S12. Hematoxylin and Eosin staining of xenografts established from bevacizumab-na�ve GBMs; Supplementary Figure S13. Comparison of xenografts from BRGs versus xenografts from bevacizumab-na�ve GBMs; Supplementary Figure S14. Murine MRI of intracranial BRG-derived xenografts reveals loss of the ability of VEGF blockade to reduce vascular permeability and fractional blood volume; Supplementary Figure S15. Reduced c-Met expression after transducing BRG-derived SF7796 xenograft cells with c-Met shRNA; Supplementary Figure S16. Effects of c-Met knockdown on brain slice invasion in U87-BevR cells; Supplementary Figure S17. Altered morphology in BRG cells after transduction with shRNA targeting c-Met; Supplementary Figure S18. C-Met knockdown alters brain slice invasion in BRG-derived SF7796 cells; Supplementary Figure S19. Hematoxylin and eosin stainings of intracranial SF7796/shControl and SF7796/shCmet1 xenografts; Supplementary Figure S20. Transduction of U87 with retrovirus derived from pBABE-Puro-Tpr-met leads to increased Tpr-met phosphorylation.
Supplementary Data 3 from Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Authors: Iglesia Michael D. , Vincent Benjamin G. , Parker Joel S. , Hoadley Katherine A. , Carey Lisa A. , Perou Charles M. , Serody Jonathan S.
Published: April 2023

XLSX file - 298K, Unique sample IDs allowing TCGA breast and ovarian data sets to be downloaded from CGHub.
Supplementary Figure 5 from Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma
Authors: Fabre Claire , Mimura Naoya , Bobb Kathryn , Kong Sun-Young , Gorgun Güllü , Cirstea Diana , Hu Yiguo , Minami Jiro , Ohguchi Hiroto , Zhang Jie , Meshulam Jeffrey , Carrasco Ruben D. , Tai Yu-Tzu , Richardson Paul G. , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

PDF file, 41K, Western-Blot JNK ERK of osteoclasts treated with PBS-1086.
Supplementary Figures S1-S5 from Low Expression of the E3 Ubiquitin Ligase CBL Confers Chemoresistance in Human Pancreatic Cancer and Is Targeted by Epidermal Growth Factor Receptor Inhibition
Authors: Kadera Brian E. , Toste Paul A. , Wu Nanping , Li Luyi , Nguyen Andrew H. , Dawson David W. , Donahue Timothy R.
Published: April 2023

Supplementary Figures S1-S5. Figure S1. MTT assays of CBL knockdown versus isogenic parental PDAC cell lines in serum-supplemented media. Figure S2. Immunoblots of L3.6plCBL siRNA cells versus control highlights autoactivation of EGFR and downstream pAKT when treated with chemotherapy. Figure S3. Chemiluminescent images of a phospho-receptor tyrosine kinase array performed in chemotherapy-treated L3.6plCBL siRNA cells versus control. Figure S4. qRT-PCR, immunoblots and photographs of L3.6plCBL shRNA and Panc-1CBL shRNA tumors versus controls verifies stable gene knockdown and gross similarities between tumors prior to the start of chemotherapy. Figure S5. Photographs of L3.6pl subcutaneous xenografts in NOD-scid-IL2Rγnull mice at the time of necropsy reveals qualitatively that chemoresistance to gemcitabine induced by CBL knockdown is abrogated by the addition of erlotinib.
Supplementary Table S3 from miR-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A
Authors: Yin Yuan , Zhang Binbin , Wang Weili , Fei Bojian , Quan Chao , Zhang Jiwei , Song Mingxu , Bian Zehua , Wang Qifeng , Ni Shujuan , Hu Yaling , Mao Yong , Zhou Leyuan , Wang Yugang , Yu Jian , Du Xiang , Hua Dong , Huang Zhaohui
Published: April 2023

Table S3. Downregulated transcripts in miR-204-5p transfected HCT116 cells
Supplementary Methods and Tables from AMACR Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance
Authors: Li Chien-Feng , Fang Fu-Min , Lan Jui , Wang Jun-Wen , Kung Hsing-Jien , Chen Li-Tzong , Chen Tzu-Ju , Li Shau-Hsuan , Wang Yu-Hui , Tai Hui-Chun , Yu Shih-Chen , Huang Hsuan-Ying
Published: April 2023

The file contains Supplementary Methods and Tables. TableTable -S1. Clinicopathologic characters of 105 myxofibrosarcoma Table-S2. Univariateand multivariate survivalanalyses for prognostic factors in 89 patients with follow-up Table-S3. Correlations between AMACR and SKP2 immunoexpression TableTable -S4. Results of Cox multivariate analyses in relation to DSS and MeFS in a subset cohort containing informative immunohistochemical data of both AMACR and SKP2 Table-S5Three differentially expressed cell cycle-associatedgenesin AMACR-knockdownmyxofibrosarcoma cell lines Table -S6. Correlations between AMACR, Cyclin D1, Cyclin T2, and Ki-67 immunoexpression
Supplementary Figure S2 from miR-204-5p Inhibits Proliferation and Invasion and Enhances Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating RAB22A
Authors: Yin Yuan , Zhang Binbin , Wang Weili , Fei Bojian , Quan Chao , Zhang Jiwei , Song Mingxu , Bian Zehua , Wang Qifeng , Ni Shujuan , Hu Yaling , Mao Yong , Zhou Leyuan , Wang Yugang , Yu Jian , Du Xiang , Hua Dong , Huang Zhaohui
Published: April 2023

Figure S2. miR-204-3p showed no significant effect on CRC cell growth. A and B, The expression of miR-204-3p in 6 different CRC cells (A) and tissues (B) was much lower than that of miR-204-5p. C and D, Overexpression of miR-204-3p in LoVo (C) and HCT116 (D) cells did not affect their rates of proliferation. The cell numbers were determined using the Cell Counting Kit-8 assay after transfection. E and F, Inhibition of miR-204-3p in LoVo (E) and HCT116 (F) cells stably expressing miR-204 did not affect their rates of proliferation.
Figure-S4 from AMACR Amplification in Myxofibrosarcomas: A Mechanism of Overexpression That Promotes Cell Proliferation with Therapeutic Relevance
Authors: Li Chien-Feng , Fang Fu-Min , Lan Jui , Wang Jun-Wen , Kung Hsing-Jien , Chen Li-Tzong , Chen Tzu-Ju , Li Shau-Hsuan , Wang Yu-Hui , Tai Hui-Chun , Yu Shih-Chen , Huang Hsuan-Ying
Published: April 2023

Figure-S4 AMACR expression does not contribute to tumor angiogenesis. In NMFH-1 (upper) and NMFH-2 (lower) cell lines, the HUVEC tube-forming capability is not significantly attenuated by conditioned media following interference with shAMACR, with similar formation of vascular network as plotted in the histograms.
Data Supplement from Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma
Authors: Trabucco Sally E. , Gerstein Rachel M. , Evens Andrew M. , Bradner James E. , Shultz Leonard D. , Greiner Dale L. , Zhang Hong
Published: April 2023

Supplementary Figure S1. Reports cell cycle analysis after 4 days of drug treatment.
Suppl Table S3 from RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma
Authors: Mi Shijun , Lin Mingyan , Brouwer-Visser Jurriaan , Heim Jennifer , Smotkin David , Hebert Tiffany , Gunter Marc J. , Goldberg Gary L. , Zheng Deyou , Huang Gloria S.
Published: April 2023

Table S3. Gene Ontology Terms Enriched among Differentially Expressed Genes as identified by the DAVID Bioinformatics.
Suppl Table S2 from RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma
Authors: Mi Shijun , Lin Mingyan , Brouwer-Visser Jurriaan , Heim Jennifer , Smotkin David , Hebert Tiffany , Gunter Marc J. , Goldberg Gary L. , Zheng Deyou , Huang Gloria S.
Published: April 2023

Table S2. Canonical Pathways Enriched among Differentially Expressed Genes as determined by Ingenuity Pathway Analysis.
Supplementary Figure 5 from Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients
Authors: Litvinov Ivan V. , Cordeiro Brendan , Huang Yuanshen , Zargham Hanieh , Pehr Kevin , Doré Marc-André , Gilbert Martin , Zhou Youwen , Kupper Thomas S. , Sasseville Denis
Published: April 2023

PDF file - 132KB, Effect of anacardic acid on expression of SYCP1 mRNA in CTCL patient-derived cell lines.
Supplementary Methods, Figures S1-S7 from Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Authors: Uppal Hirdesh , Doudement Estelle , Mahapatra Kaushiki , Darbonne Walter C. , Bumbaca Daniela , Shen Ben-Quan , Du Xiaoyan , Saad Ola , Bowles Kristin , Olsen Steve , Lewis Phillips Gail D. , Hartley Dylan , Sliwkowski Mark X. , Girish Sandhya , Dambach Donna , Ramakrishnan Vanitha
Published: April 2023

Supplementary Methods, Figures S1-S7 Suppl. Fig. S1, Differentiation of hematopoietic stem cells (CD133+/CD34+) into immature megakarytocytes Suppl. Fig. S2, T-DM1 does not directly induce platelet aggregation in washed platelets Suppl. Fig. S3, At high concentrations, DM1 inhibits agonist-induced platelet aggregation in platelet-rich plasma Suppl. Fig. S4, DM1 conjugates alter the morphology of megakaryocytes Suppl. Fig. S5, Uptake of T-[3H]DM1 varies by differentiation stage Suppl. Fig. S6, HER2 is not expressed on megakaryocytes or platelets Suppl. Fig. S7, Prolonged exposure to T-DM1 results in disruption of cytoskeletal structure in maturing megakaryocytes
Supplementary Table S3C from Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Authors: Somlo George , Atzori Francesco , Strauss Lewis C. , Geese William J. , Specht Jennifer M. , Gradishar William J. , Rybicki Alissa , Sy Oumar , Vahdat Linda T. , Cortes Javier
Published: April 2023

PDF file - 25 KB, Table S3C . Changes in biomarkers in patients treated with single agent dasatinib on trials CA180059 + CA180088
Supplementary Figure 2 from Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients
Authors: Litvinov Ivan V. , Cordeiro Brendan , Huang Yuanshen , Zargham Hanieh , Pehr Kevin , Doré Marc-André , Gilbert Martin , Zhou Youwen , Kupper Thomas S. , Sasseville Denis
Published: April 2023

PDF file - 164KB, Detailed description of RT-PCR analysis of CT genes expression in CTCL patient-derived cell lines.
Supplementary Table 1 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Authors: Filipazzi Paola , Pilla Lorenzo , Mariani Luigi , Patuzzo Roberto , Castelli Chiara , Camisaschi Chiara , Maurichi Andrea , Cova Agata , Rigamonti Gianluigi , Giardino Felicetta , Di Florio Annabella , Asioli Marco , Frati Paola , Sovena Gloria , Squarcina Paola , Maio Michele , Danielli Riccardo , Chiarion-Sileni Vanna , Villa Antonello , Lombardo Claudia , Tragni Gabrina , Santinami Mario , Parmiani Giorgio , Rivoltini Licia
Published: April 2023

PDF file - 44K, Patient characteristics
Supplementary Figure 5 from Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Authors: Filipazzi Paola , Pilla Lorenzo , Mariani Luigi , Patuzzo Roberto , Castelli Chiara , Camisaschi Chiara , Maurichi Andrea , Cova Agata , Rigamonti Gianluigi , Giardino Felicetta , Di Florio Annabella , Asioli Marco , Frati Paola , Sovena Gloria , Squarcina Paola , Maio Michele , Danielli Riccardo , Chiarion-Sileni Vanna , Villa Antonello , Lombardo Claudia , Tragni Gabrina , Santinami Mario , Parmiani Giorgio , Rivoltini Licia
Published: April 2023

PDF file - 31K, Polyfunctional analysis of vaccine-induced T-cell cultures
Data Supplement from Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR–Based Platform
Authors: Guo Wei , Yang Xin-Rong , Sun Yun-Fan , Shen Min-Na , Ma Xiao-Lu , Wu Jiong , Zhang Chun-Yan , Zhou Yan , Xu Yang , Hu Bo , Zhang Xin , Zhou Jian , Fan Jia
Published: April 2023

Supplementary Table S1. Sensitivity of two RNA isolation and two cDNA synthesis methods with the Hep3B cell line. Supplementary Table S2. Precision of the optimized system. Supplementary Table S3. Diagnostic value of EpCAMmRNA+ CTCs in HCC subgroups. Supplementary Table S4. Diagnostic value of the combination of EpCAMmRNA+ CTC and AFP in HCC subgroups. Supplementary Table S5. Univariate and multivariate Cox proportional regression analysis of factors associated with recurrence/progression.
Supplementary Table 2 from Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis
Authors: Dal Molin Marco , Zhang Ming , de Wilde Roeland F. , Ottenhof Niki A. , Rezaee Neda , Wolfgang Christopher L. , Blackford Amanda , Vogelstein Bert , Kinzler Kenneth W. , Papadopoulos Nickolas , Hruban Ralph H. , Maitra Anirban , Wood Laura D.
Published: April 2023

Supplementary Table 2. Somatic mutations identified in exome sequencing of VLTSs
Supplemental Table 1 from The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB
Authors: Deng Changchun , Lipstein Mark , Rodriguez Richard , Serrano Xavier O. Jirau , McIntosh Christine , Tsai Wei-Yann , Wasmuth Andrew S. , Jaken Susan , O'Connor Owen A.
Published: April 2023

Supplemental Table 1. IC50 of LY2409881 in lymphoma cell lines.
Supplemental Figure S8 from A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients
Authors: Guo Yuna , Kenney S. Ray , Cook Linda , Adams Sarah F. , Rutledge Teresa , Romero Elsa , Oprea Tudor I. , Sklar Larry A. , Bedrick Edward , Wiggins Charles L. , Kang Huining , Lomo Lesley , Muller Carolyn Y. , Wandinger-Ness Angela , Hudson Laurie G.
Published: April 2023

Supplemental Figure S8. RhoA activity is insensitive to ketorolac treatment.
Supplementary Table 3 from A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Authors: Dvorkina Maria , Nieddu Valentina , Chakelam Shalini , Pezzolo Annalisa , Cantilena Sandra , Leite Ana Paula , Chayka Olesya , Regad Tarik , Pistorio Angela , Sementa Angela Rita , Virasami Alex , Barton Jack , Montano Ximena , Lechertier Tanguy , Brindle Nicola , Morgenstern Daniel , Lebras Morgane , Burns Alan J. , Saunders Nigel J. , Hodivala-Dilke Kairbaan , Bagella Luigi , De The Hugues , Anderson John , Sebire Neil , Pistoia Vito , Sala Arturo , Salomoni Paolo
Published: April 2023

Pathway analysis
Supplementary Table S1 from Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer
Authors: Koido Shigeo , Homma Sadamu , Okamoto Masato , Takakura Kazuki , Mori Masako , Yoshizaki Shinji , Tsukinaga Shintaro , Odahara Shunichi , Koyama Seita , Imazu Hiroo , Uchiyama Kan , Kajihara Mikio , Arakawa Hiroshi , Misawa Takeyuki , Toyama Yoichi , Yanagisawa Satoru , Ikegami Masahiro , Kan Shin , Hayashi Kazumi , Komita Hideo , Kamata Yuko , Ito Masaki , Ishidao Takefumi , Yusa Sei-ichi , Shimodaira Shigetaka , Gong Jianlin , Sugiyama Haruo , Ohkusa Toshifumi , Tajiri Hisao
Published: April 2023

Adverse events during the first 3 courses of treatment.
Supplemental Table 7 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Authors: Shapiro Geoffrey I. , Bell-McGuinn Katherine M. , Molina Julian R. , Bendell Johanna , Spicer James , Kwak Eunice L. , Pandya Susan S. , Millham Robert , Borzillo Gary , Pierce Kristen J. , Han Lixin , Houk Brett E. , Gallo Jorge D. , Alsina Maria , Braña Irene , Tabernero Josep
Published: April 2023

Supplemental Table 7. Results of the pharmacodynamic analysis of tumor-associated biomarkers following treatment with PF-05212384
Supplemental Table 4 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Authors: Shapiro Geoffrey I. , Bell-McGuinn Katherine M. , Molina Julian R. , Bendell Johanna , Spicer James , Kwak Eunice L. , Pandya Susan S. , Millham Robert , Borzillo Gary , Pierce Kristen J. , Han Lixin , Houk Brett E. , Gallo Jorge D. , Alsina Maria , Braña Irene , Tabernero Josep
Published: April 2023

Supplemental Table 4. Cycle 2 results of the pharmacokinetic analysis of PF-05212384 administered at the maximum tolerated dose
Supplemental Table 2 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Authors: Shapiro Geoffrey I. , Bell-McGuinn Katherine M. , Molina Julian R. , Bendell Johanna , Spicer James , Kwak Eunice L. , Pandya Susan S. , Millham Robert , Borzillo Gary , Pierce Kristen J. , Han Lixin , Houk Brett E. , Gallo Jorge D. , Alsina Maria , Braña Irene , Tabernero Josep
Published: April 2023

Supplemental Table 2. Additional study results on treatment-related adverse events at dose levels above the maximum tolerated dose
Supplemental Table 1 from First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Authors: Shapiro Geoffrey I. , Bell-McGuinn Katherine M. , Molina Julian R. , Bendell Johanna , Spicer James , Kwak Eunice L. , Pandya Susan S. , Millham Robert , Borzillo Gary , Pierce Kristen J. , Han Lixin , Houk Brett E. , Gallo Jorge D. , Alsina Maria , Braña Irene , Tabernero Josep
Published: April 2023

Supplemental Table 1. Additional study results on treatment-related adverse events at dose levels below the maximum tolerated dose
Supplementary Methods and Figure Legend from Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Authors: Cui Yunfeng , Brosnan Jacqueline A. , Blackford Amanda L. , Sur Surojit , Hruban Ralph H. , Kinzler Kenneth W. , Vogelstein Bert , Maitra Anirban , Diaz Luis A. , Iacobuzio-Donahue Christine A. , Eshleman James R.
Published: April 2023

PDF file, 76K.
Supplementary Figure Legend from LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
Authors: Yeung Jacky T. , Hamilton Ronald L. , Ohnishi Koji , Ikeura Maki , Potter Douglas M. , Nikiforova Marina N. , Ferrone Soldano , Jakacki Regina I. , Pollack Ian F. , Okada Hideho
Published: April 2023

PDF file - 65K
Supplementary Figure 1 from LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma
Authors: Yeung Jacky T. , Hamilton Ronald L. , Ohnishi Koji , Ikeura Maki , Potter Douglas M. , Nikiforova Marina N. , Ferrone Soldano , Jakacki Regina I. , Pollack Ian F. , Okada Hideho
Published: April 2023

PDF file - 75K, Microsatellite markers on chromosome 6.
supplemental legend from Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Authors: Lou Yanyan , Diao Lixia , Cuentas Edwin Roger Parra , Denning Warren L. , Chen Limo , Fan You Hong , Byers Lauren A. , Wang Jing , Papadimitrakopoulou Vassiliki A. , Behrens Carmen , Rodriguez Jaime Canales , Hwu Patrick , Wistuba Ignacio I. , Heymach John V. , Gibbons Don L.
Published: April 2023

supplemental legend
MET supplementary methods from Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Authors: Lou Yanyan , Diao Lixia , Cuentas Edwin Roger Parra , Denning Warren L. , Chen Limo , Fan You Hong , Byers Lauren A. , Wang Jing , Papadimitrakopoulou Vassiliki A. , Behrens Carmen , Rodriguez Jaime Canales , Hwu Patrick , Wistuba Ignacio I. , Heymach John V. , Gibbons Don L.
Published: April 2023

MET supplementary methods
Supplementary Figure 4 from Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry
Authors: Mulligan Anna Marie , Raitman Irene , Feeley Linda , Pinnaduwage Dushanthi , Nguyen Linh T. , O'Malley Frances P. , Ohashi Pamela S. , Andrulis Irene L.
Published: April 2023

Supplementary Figure S4: Confirmation of CXCL10 and CXCR3 overexpression in CXCL10-CXCR3 cells. (A) ELISA showing the average level of CXCL10 secreted into the media over 24h by 1x107 CXCL10-CXCR3 or empty vector cells, respectively. (B) Flow cytometry results showing the mean fluorescence intensity of CXCR3 and the percent of CXCR3 positive cells in the CXCL10-CXCR3 and empty vector cell populations, respectively. Filled histograms represent isotype-matched control, and empty histograms represent CXCR3-PE.
Supplementary Table 1 from Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
Authors: Vidal August , Muñoz Clara , Guillén María-José , Moretó Jemina , Puertas Sara , Martínez-Iniesta María , Figueras Agnés , Padullés Laura , García-Rodriguez Francisco J. , Berdiel-Acer Mireia , Pujana Miguel A. , Salazar Ramón , Gil-Martin Marta , Martí Lola , Ponce Jordi , Molleví David G. , Capella Gabriel , Condom Enric , Viñals Francesc , Huertas Dori , Cuevas Carmen , Esteller Manel , Avilés Pablo , Villanueva Alberto
Published: April 2023

PDF file, 80K, Extensive histopathologic regression criteria analysis in post-chemotherapy engarfted OVA1X tumor.
Supplementary Figure 1 from Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
Authors: Vidal August , Muñoz Clara , Guillén María-José , Moretó Jemina , Puertas Sara , Martínez-Iniesta María , Figueras Agnés , Padullés Laura , García-Rodriguez Francisco J. , Berdiel-Acer Mireia , Pujana Miguel A. , Salazar Ramón , Gil-Martin Marta , Martí Lola , Ponce Jordi , Molleví David G. , Capella Gabriel , Condom Enric , Viñals Francesc , Huertas Dori , Cuevas Carmen , Esteller Manel , Avilés Pablo , Villanueva Alberto
Published: April 2023

PDF file, 282K, Presence of aberrant mitotic figures in engrafted OVA1X tumors analyzed by co-immunostaining with anti-H3S10ph, anti-tubulin. Chromosomes were labeled with DAPI.
Supplementary Table S1 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Authors: Besse Benjamin , Le Moulec Sylvestre , Mazières Julien , Senellart Hélène , Barlesi Fabrice , Chouaid Christos , Dansin Eric , Bérard Henri , Falchero Lionel , Gervais Radj , Robinet Gilles , Ruppert Anne-Marie , Schott Roland , Léna Hervé , Clément-Duchêne Christelle , Quantin Xavier , Souquet Pierre Jean , Trédaniel Jean , Moro-Sibilot Denis , Pérol Maurice , Madroszyk Anne-Catherine , Soria Jean-Charles
Published: April 2023

Supplementary Table S1: Best response rates for primary tumors and metastases in 67 patients (ITT population) treated with bevacizumab plus paclitaxel and carboplatin
Supplementary Tables 1 - 2 from In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
Authors: Fonte Eleonora , Apollonio Benedetta , Scarfò Lydia , Ranghetti Pamela , Fazi Claudia , Ghia Paolo , Caligaris-Cappio Federico , Muzio Marta
Published: April 2023

PDF file - 89K, Supplementary Table 1 complete list of genes Supplementary Table 2 The array consists of a panel of 96 primer sets used for the amplification of 84 genes relevant to the apoptosis pathway
Supplementary Figure 3 from MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation
Authors: Wermke Martin , Schmidt Anne , Middeke Jan Moritz , Sockel Katja , von Bonin Malte , Schönefeldt Claudia , Mair Sabine , Plodeck Verena , Laniado Michael , Weiss Günter , Schetelig Johannes , Ehninger Gerhard , Theurl Igor , Bornhäuser Martin , Platzbecker Uwe
Published: April 2023

PDF file - 170K, Cumulative incidence curves of acute GvHD grade 2 to 4 with respect to LIC, transfusion burden and ferritin
Supplementary Figure 2 from Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Authors: Cheng Zhixiang , Gong Yuanying , Ma Yufang , Lu Kaihua , Lu Xiang , Pierce Larry A. , Thompson Reid C. , Muller Susanne , Knapp Stefan , Wang Jialiang
Published: April 2023

PDF file - 4 MB, (A) Normal human neural progenitor (NHNP) cells were treated with JQ1 at various concentrations as indicated. Five days after treatment, cell viability was determined by the CellTiter-Glo assay kit and normalized to the values of vehicle-treated cells. (B) Three days after JQ1 treatment, caspase activity was determined as described in Figure 2B
Supplementary Table S3 from Global Transcriptional Changes Following Statin Treatment in Breast Cancer
Authors: Bjarnadottir Olöf , Kimbung Siker , Johansson Ida , Veerla Srinivas , Jönsson Mats , Bendahl Pär-Ola , Grabau Dorthe , Hedenfalk Ingrid , Borgquist Signe
Published: April 2023

Supplementary Table S3. Transcription factors identified with significant enrichment using the transcription factor binding analysis program, SMART
Supplementary Fig. S2 from Global Transcriptional Changes Following Statin Treatment in Breast Cancer
Authors: Bjarnadottir Olöf , Kimbung Siker , Johansson Ida , Veerla Srinivas , Jönsson Mats , Bendahl Pär-Ola , Grabau Dorthe , Hedenfalk Ingrid , Borgquist Signe
Published: April 2023

Supplementary Fig. S2. RT-qPCR validation of the expression of five selected genes. A) Expression of HMGCR, DUSP1, RHOB, JUN and FOS measured by microarray and RT-qPCR respectively. B) Change in HMGCR expression in all patients by RT-qPCR.
Supplementary Table S4 from TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Authors: Sun Tiantian , Du Wan , Xiong Hua , Yu Yanan , Weng Yurong , Ren Linlin , Zhao Huijun , Wang Yingchao , Chen Yingxuan , Xu Jie , Xiang Yongbing , Qin Wenxin , Cao Weibiao , Zou Weiping , Chen Haoyan , Hong Jie , Fang Jing-Yuan
Published: April 2023

Supplementary Table S4. Proteins identified by mass spectrometry from the TMEFF2 co-immunoprecipitate sample.
Supplementary Fig. S4 from Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models
Authors: Song Gina , Darr David B. , Santos Charlene M. , Ross Mark , Valdivia Alain , Jordan Jamie L. , Midkiff Bentley R. , Cohen Stephanie , Nikolaishvili-Feinberg Nana , Miller C. Ryan , Tarrant Teresa K. , Rogers Arlin B. , Dudley Andrew C. , Perou Charles M. , Zamboni William C.
Published: April 2023

Supplementary Fig. S4. Size distribution of baseline blood vessels in the C3-TAg tumors and the T11 tumors
Supplementary Fig. S3 from Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models
Authors: Song Gina , Darr David B. , Santos Charlene M. , Ross Mark , Valdivia Alain , Jordan Jamie L. , Midkiff Bentley R. , Cohen Stephanie , Nikolaishvili-Feinberg Nana , Miller C. Ryan , Tarrant Teresa K. , Rogers Arlin B. , Dudley Andrew C. , Perou Charles M. , Zamboni William C.
Published: April 2023

Supplementary Fig. S3. Profiling of collagen in basal-like C3-TAg model and claudin-low T11 model at baseline and at 96 h after administration of PLD or NL-doxo at 6 mg/kg I.V. x 1 via tail vein
Supplementary Table S1 from TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Authors: Sun Tiantian , Du Wan , Xiong Hua , Yu Yanan , Weng Yurong , Ren Linlin , Zhao Huijun , Wang Yingchao , Chen Yingxuan , Xu Jie , Xiang Yongbing , Qin Wenxin , Cao Weibiao , Zou Weiping , Chen Haoyan , Hong Jie , Fang Jing-Yuan
Published: April 2023

Supplementary Table S1. The extent of inflammation in pre-cancerous lesions of Renji dataset.
Supplementary Tables from A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
Authors: Lim Ho Yeong , Heo Jeong , Choi Hye Jin , Lin Cheng-Yao , Yoon Jung-Hwan , Hsu Chiun , Rau Kun-Ming , Poon Ronnie T.P. , Yeo Winnie , Park Joong-Won , Tay Miah Hiang , Hsieh Wen-Son , Kappeler Christian , Rajagopalan Prabhu , Krissel Heiko , Jeffers Michael , Yen Chia-Jui , Tak Won Young
Published: April 2023

Supplementary Tables. Supplementary Table 1. Pre-defined dose modification levels for sorafenib and refametinib Supplementary Table 2. Single-dose refametinib and its metabolite M17 geometric mean (% coefficient of variation) pharmacokinetic parameters on cycle 1 day âˆ’3 Supplementary Table 3. Multiple-dose refametinib and its metabolite M17, and sorafenib and its metabolite M2, geometric mean (% coefficient of variation) pharmacokinetic parameters on cycle 2 day 1 Supplementary Table 4. Incidence of treatment-emergent adverse events (occurring in {greater than or equal to}25% of patients), by CTCAE grade Supplementary Table 5. Incidence of adverse events related to refametinib and sorafenib (occurring in {greater than or equal to}15% of patients), by CTCAE grade Supplementary Table 6. Incidence of treatment-emergent serious adverse events (occurring in {greater than or equal to}2 patients), by CTCAE grades 2-5 Supplementary Table 7. Incidence of treatment-emergent serious adverse events (occurring in {greater than or equal to}2 patients) of CTCAE grades 3-5, related to both study drugs
Supplementary Figure 3 from Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
Authors: Kalota Anna , Jeschke Grace R. , Carroll Martin , Hexner Elizabeth O.
Published: April 2023

PDF file - 33K, Supplementary Figure S3. Plasma cytokine concentration in MPN patients and normal donors.
Supplementary Figure 1 from Intrinsic Resistance to JAK2 Inhibition in Myelofibrosis
Authors: Kalota Anna , Jeschke Grace R. , Carroll Martin , Hexner Elizabeth O.
Published: April 2023

PDF file - 33K, Supplementary Figure S1: Basal STAT5 and STAT3 expression and phosphorylation are similar across MPNs and normal donors
Figure S6 from Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Kannan Anbarasu , Wells Robert B. , Sivakumar Subramaniam , Komatsu Satoshi , Singh Karan P. , Samten Buka , Philley Julie V. , Sauter Edward R. , Ikebe Mitsuo , Idell Steven , Gupta Sudeep , Dasgupta Santanu
Published: April 2023

Association between SH3GL2/MFN2 loss and progression.
Figure S5 from Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Kannan Anbarasu , Wells Robert B. , Sivakumar Subramaniam , Komatsu Satoshi , Singh Karan P. , Samten Buka , Philley Julie V. , Sauter Edward R. , Ikebe Mitsuo , Idell Steven , Gupta Sudeep , Dasgupta Santanu
Published: April 2023

Impact of SH3GL2 overexpression in vivo.
Figure S3 from Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Kannan Anbarasu , Wells Robert B. , Sivakumar Subramaniam , Komatsu Satoshi , Singh Karan P. , Samten Buka , Philley Julie V. , Sauter Edward R. , Ikebe Mitsuo , Idell Steven , Gupta Sudeep , Dasgupta Santanu
Published: April 2023

Phosphorylation sites in SH3GL2.
Supplementary Table 2 from Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients
Authors: Mayerhoefer Marius E. , Karanikas Georgios , Kletter Kurt , Prosch Helmut , Kiesewetter Barbara , Skrabs Cathrin , Porpaczy Edit , Weber Michael , Pinker-Domenig Katja , Berzaczy Dominik , Hoffmann Martha , Sillaber Christian , Jaeger Ulrich , Müllauer Leonhard , Simonitsch-Klupp Ingrid , Dolak Werner , Gaiger Alexander , Ubl Philipp , Lukas Julius , Raderer Markus
Published: April 2023

PDF file - 16KB, Region-based sensitivities and specificities (and 95% confidence intervals) of DWI-MRI in patients with DLBCL, follicular lymphoma, and Hodgkin lymphoma.
Figure S2 from Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Kannan Anbarasu , Wells Robert B. , Sivakumar Subramaniam , Komatsu Satoshi , Singh Karan P. , Samten Buka , Philley Julie V. , Sauter Edward R. , Ikebe Mitsuo , Idell Steven , Gupta Sudeep , Dasgupta Santanu
Published: April 2023

SH3GL2 introduction alters various growth regulatory molecules.
Supplementary Figure Legends from Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients
Authors: Mayerhoefer Marius E. , Karanikas Georgios , Kletter Kurt , Prosch Helmut , Kiesewetter Barbara , Skrabs Cathrin , Porpaczy Edit , Weber Michael , Pinker-Domenig Katja , Berzaczy Dominik , Hoffmann Martha , Sillaber Christian , Jaeger Ulrich , Müllauer Leonhard , Simonitsch-Klupp Ingrid , Dolak Werner , Gaiger Alexander , Ubl Philipp , Lukas Julius , Raderer Markus
Published: April 2023

PDF file - 62KB
Data Supplement from Intraperitoneal Oxidative Stress in Rabbits with Papillomavirus-Associated Head and Neck Cancer Induces Tumoricidal Immune Response That Is Adoptively Transferable
Authors: Rossmann Annette , Mandic Robert , Heinis Jochen , Höffken Helmut , Küssner Oliver , Kinscherf Ralf , Weihe Eberhard , Bette Michael
Published: April 2023

Supplementary Table 2B. Complete RT2 Profiler PCR Array 2. Overview of all genes analyzed by the RT2 Profiler PCR Array (SABiosciences, PANZ-052ZA). Fold changes of mRNA expression level measured in remitting VX2 tumors in the cause of the O3/O2-PP therapy (Regression, n=6) were calculated in reference to mRNA level measured in growing VX2 tumors of sham treated animals (Progression, n=6). Regulation of mRNA level is marked by â†‘ (up) or â†“ (down). Statistic differences were calculated by the paired t-test and marked as: *p<0.05; **p<0.01; ***p<0.001; n.s. not significant.
Data Supplement from Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth
Authors: Sankar Savita , Theisen Emily R. , Bearss Jared , Mulvihill Timothy , Hoffman Laura M. , Sorna Venkataswamy , Beckerle Mary C. , Sharma Sunil , Lessnick Stephen L.
Published: April 2023

Supplementary Table S1. Differentially Expressed Genes by RNA-seq.
Supplementary Table 3 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Authors: Schneider Bryan P. , Li Lang , Radovich Milan , Shen Fei , Miller Kathy D. , Flockhart David A. , Jiang Guanglong , Vance Gail , Gardner Laura , Vatta Matteo , Bai Shaochun , Lai Dongbing , Koller Daniel , Zhao Fengmin , O'Neill Anne , Smith Mary Lou , Railey Elda , White Carol , Partridge Ann , Sparano Joseph , Davidson Nancy E. , Foroud Tatiana , Sledge George W.
Published: April 2023

Supplementary Table 3 - Summary of SNPs with p<0.0001 in EA patients with Grade 3-4 NE in E5103.
Supplementary Table 1 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Authors: Schneider Bryan P. , Li Lang , Radovich Milan , Shen Fei , Miller Kathy D. , Flockhart David A. , Jiang Guanglong , Vance Gail , Gardner Laura , Vatta Matteo , Bai Shaochun , Lai Dongbing , Koller Daniel , Zhao Fengmin , O'Neill Anne , Smith Mary Lou , Railey Elda , White Carol , Partridge Ann , Sparano Joseph , Davidson Nancy E. , Foroud Tatiana , Sledge George W.
Published: April 2023

Supplementary Table 1 - Candidate SNPs genotyped in EA patients in E1199.
Supplemental Methods from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Authors: Schneider Bryan P. , Li Lang , Radovich Milan , Shen Fei , Miller Kathy D. , Flockhart David A. , Jiang Guanglong , Vance Gail , Gardner Laura , Vatta Matteo , Bai Shaochun , Lai Dongbing , Koller Daniel , Zhao Fengmin , O'Neill Anne , Smith Mary Lou , Railey Elda , White Carol , Partridge Ann , Sparano Joseph , Davidson Nancy E. , Foroud Tatiana , Sledge George W.
Published: April 2023

GWAS with E5103 samples and OpenArray Genotyping with E1199 samples.
Supplementary Methods from Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer
Authors: Ryner Lisa , Guan Yinghui , Firestein Ron , Xiao Yuanyuan , Choi Younjeong , Rabe Christina , Lu Shan , Fuentes Eloisa , Huw Ling-Yuh , Lackner Mark R. , Fu Ling , Amler Lukas C. , Bais Carlos , Wang Yulei
Published: April 2023

Supplementary Methods. Detailed methods descriptions for supplementary publication.
Supplemental Figure Legends from Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Authors: Chapiro Julius , Sur Surojit , Savic Lynn Jeanette , Ganapathy-Kanniappan Shanmugasundaram , Reyes Juvenal , Duran Rafael , Thiruganasambandam Sivarajan Chettiar , Moats Cassandra Rae , Lin MingDe , Luo Weibo , Tran Phuoc T. , Herman Joseph M. , Semenza Gregg L. , Ewald Andrew J. , Vogelstein Bert , Geschwind Jean-François
Published: April 2023

This files contains the Supplemental Figure legends.
Supplemental Figure 3 from Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Authors: Chapiro Julius , Sur Surojit , Savic Lynn Jeanette , Ganapathy-Kanniappan Shanmugasundaram , Reyes Juvenal , Duran Rafael , Thiruganasambandam Sivarajan Chettiar , Moats Cassandra Rae , Lin MingDe , Luo Weibo , Tran Phuoc T. , Herman Joseph M. , Semenza Gregg L. , Ewald Andrew J. , Vogelstein Bert , Geschwind Jean-François
Published: April 2023

Demonstration of Treatment-related Toxicity using Survival Analysis and Organ Histology.
Supplemental Figure 2 from Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
Authors: Chapiro Julius , Sur Surojit , Savic Lynn Jeanette , Ganapathy-Kanniappan Shanmugasundaram , Reyes Juvenal , Duran Rafael , Thiruganasambandam Sivarajan Chettiar , Moats Cassandra Rae , Lin MingDe , Luo Weibo , Tran Phuoc T. , Herman Joseph M. , Semenza Gregg L. , Ewald Andrew J. , Vogelstein Bert , Geschwind Jean-François
Published: April 2023

This figure provides the overview of the results for the viability experiments in the 3D in vitro model.
supplementary table from A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
Authors: Lee Ji Yun , Sun Jong-Mu , Lim Sung Hee , Kim Hae Su , Yoo Kwai Han , Jung Ki Sun , Song Haa-Na , Ku Bo Mi , Koh Jiae , Bae Yeon-Hee , Lee Se-Hoon , Ahn Jin Seok , Park Keunchil , Ahn Myung-Ju
Published: April 2023

Supplementary Table 1. Best response to treatment among response-evaluable patients treated with RPIID (n = 43)
Supplementary Table S5 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Authors: Braggio Esteban , Van Wier Scott , Ojha Juhi , McPhail Ellen , Asmann Yan W. , Egan Jan , da Silva Jackline Ayres , Schiff David , Lopes M. Beatriz , Decker Paul A. , Valdez Riccardo , Tibes Raoul , Eckloff Bruce , Witzig Thomas E. , Stewart A. Keith , Fonseca Rafael , O'Neill Brian Patrick
Published: April 2023

Supplementary Table S5. Compendium of all the abnormalities found per patient. CN: Copy-number; HD: homozygous deletion.
Supplementary Table S2 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Authors: Braggio Esteban , Van Wier Scott , Ojha Juhi , McPhail Ellen , Asmann Yan W. , Egan Jan , da Silva Jackline Ayres , Schiff David , Lopes M. Beatriz , Decker Paul A. , Valdez Riccardo , Tibes Raoul , Eckloff Bruce , Witzig Thomas E. , Stewart A. Keith , Fonseca Rafael , O'Neill Brian Patrick
Published: April 2023

Supplementary Table S2. Description of tissue source for DNA extraction and techniques performed in each sample. * Indicates cases with insufficient material where a whole genome amplification step was required before performing the molecular tests. FFPE: formalin fixed parraffin embedded. aCGH: array-based comparative genomic hybridization; WES: whole exome sequencing.
Supplemental Figures 1-5 from Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis
Authors: Guin Sunny , Ru Yuanbin , Agarwal Neeraj , Lew Carolyn R. , Owens Charles , Comi Giacomo P. , Theodorescu Dan
Published: April 2023

Supplemental Figure 1. Heatmap for top 100 differentially expressed genes with AGL depletion in bladder cancer cell line UMUC3. Supplemental Figure 2. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for HAS2, RRAGD, VCAN, EREG and TULP3 in T24T cells with or without AGL. Supplemental Figure 3. A,B,C, Monolayer growth of UMUC3 cells with and without AGL knockdown followed by knockdown of HAS2, RRAGD and TULP3. Supplemental Figure 4. A, qRT-PCR for HAS2 in UMUC3 control and AGL knockdown cells using a second siRNA against HAS2 followed by monolayer growth assay. B, qRT-PCR for HAS2 in MGHU4 cells with AGL knockdown. C, qRT-PCR to validate knockdown of HAS2 in MGHU4 control and AGL knockdown cells followed by monolayer growth assay. Supplemental Figure 5. A, HA ELISA for UMUC3 AGL knockdown cells after knockdown of HAS2 using a new siRNA. B, HA ELISA of MGHU4 cells with or without AGL expression after HAS2 knockdown. C, Monolayer growth of T24T cells with and without AGL on treatment with 4MU. D, Monolayer growth of T24T cells with and without AGL on treatment with 4MU and HA.
Video 2 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Authors: Bacac Marina , Fauti Tanja , Sam Johannes , Colombetti Sara , Weinzierl Tina , Ouaret Djamila , Bodmer Walter , Lehmann Steffi , Hofer Thomas , Hosse Ralf J. , Moessner Ekkehard , Ast Oliver , Bruenker Peter , Grau-Richards Sandra , Schaller Teilo , Seidl Annette , Gerdes Christian , Perro Mario , Nicolini Valeria , Steinhoff Nathalie , Dudal Sherri , Neumann Sebastian , von Hirschheydt Thomas , Jaeger Christiane , Saro Jose , Karanikas Vaios , Klein Christian , Umaña Pablo
Published: April 2023

Representative videos of intravital two-photon (2P) microscopy of tumors treated with CEA TCB. Tumor cells red, T cells green.
Supplementary Figure S4 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Authors: Silva Ines P. , Salhi Amel , Giles Keith M. , Vogelsang Matjaz , Han Sung W. , Ismaili Naima , Lui Kevin P. , Robinson Eric M. , Wilson Melissa A. , Shapiro Richard L. , Pavlick Anna , Zhong Judy , Kirchhoff Tomas , Osman Iman
Published: April 2023

Clinically relevant somatic mutations identified in WT melanoma patients in the pilot cohort
Table S1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Authors: Bacac Marina , Fauti Tanja , Sam Johannes , Colombetti Sara , Weinzierl Tina , Ouaret Djamila , Bodmer Walter , Lehmann Steffi , Hofer Thomas , Hosse Ralf J. , Moessner Ekkehard , Ast Oliver , Bruenker Peter , Grau-Richards Sandra , Schaller Teilo , Seidl Annette , Gerdes Christian , Perro Mario , Nicolini Valeria , Steinhoff Nathalie , Dudal Sherri , Neumann Sebastian , von Hirschheydt Thomas , Jaeger Christiane , Saro Jose , Karanikas Vaios , Klein Christian , Umaña Pablo
Published: April 2023

List, Source and CEA binding sites of Cell Lines used in the study
Supplementary Figure S1 from Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Authors: Silva Ines P. , Salhi Amel , Giles Keith M. , Vogelsang Matjaz , Han Sung W. , Ismaili Naima , Lui Kevin P. , Robinson Eric M. , Wilson Melissa A. , Shapiro Richard L. , Pavlick Anna , Zhong Judy , Kirchhoff Tomas , Osman Iman
Published: April 2023

Our Ion Torrent targeted sequencing assay consists of a single ultraplex PCR reaction with primer sets for 207 amplicons. Data were filtered to exclude all synonymous and intronic variants. A quality score cutoff of 100 and an allele frequency of >5 were applied to eliminate low frequency artifacts.
Supplementary Figures 1-4 from Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
Authors: Filatenkov Alexander , Baker Jeanette , Mueller Antonia M.S. , Kenkel Justin , Ahn G-One , Dutt Suparna , Zhang Nigel , Kohrt Holbrook , Jensen Kent , Dejbakhsh-Jones Sussan , Shizuru Judith A. , Negrin Robert N. , Engleman Edgar G. , Strober Samuel
Published: April 2023

Supplementary Figures 1-4. Supplementary Figure 1. In vitro suppressive function of tumor-infiltrating MDSC 3 days after LTI, and analysis of CD8+CD11+ dendritic cell tumor infiltration after LTI. Supplementary Figure 2. PDL-1 and CD62L expression of tumor-infiltrating cells. Supplementary Figure 3. CT26 luc+ tumors were established in BALB/c RAG2-/- animals. 30 Gy LTI was given on day 21 after tumor induction. Bioluminescence imaging (BLI) is shown with proton emission at serial time points. Supplementary Figure 4. Model for T cell mediated remissions and reversal of the immunosuppressive tumor microenvironment